ArticleMolecular cancer therapeutics2021

First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer.

Mark D Pegram et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.